Form 4: Cassava Sciences Director Robert Gussin Granted 26,500 Stock Options Under Approved Compensation Plan

Cassava Sciences Inc. Director Robert Z. Gussin was granted 26,500 stock options with an exercise price of $2.11, effective May 23, 2025, as part of the company's amended non-employee director compensation program.

Summary

• Robert Z. Gussin, a Director of Cassava Sciences Inc. (SAVA), was granted 26,500 stock options.
• The grant occurred on May 23, 2025, with an exercise price of $2.11 per share.
• These options are exercisable immediately (May 23, 2025) and expire on May 23, 2035.
• The options were granted at a price of $0, indicating they were part of a compensation package.
• The grant is pursuant to the Amended Non-employee Director Compensation Program, which was approved by stockholders on May 23, 2025.
• The stock options will vest over a one-year period at a rate of 1/12 per month.
• Following this transaction, Mr. Gussin beneficially owns 26,500 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine stock option grant to a director under an approved compensation plan, which is a standard practice for incentivizing board members and aligning their interests with shareholders. While it implies potential future dilution, it's a neutral to slightly positive event for corporate governance and director retention.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The compensation program was approved by stockholders, indicating transparency and sound corporate governance.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• The issuance of new stock options can lead to potential future dilution for existing shareholders if exercised.

Future Outlook

The stock options will vest over a one-year period at a rate of 1/12 per month, indicating a future vesting schedule.

Industry Context

The granting of stock options to non-employee directors is a common practice across industries, including biotechnology, to attract and retain qualified board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options as part of non-employee director compensation is a standard practice in publicly traded companies, particularly in the biotech sector where long-term value creation is paramount.
• Specific comparable companies or projects are not mentioned in this filing, but such compensation structures are widely observed across companies like Biogen, Eli Lilly, or Pfizer, which also utilize equity-based incentives for their board members.
• The vesting schedule of one year is also a common approach to ensure continued commitment.

Corporate Governance

Related Party Transactions

• The grant of stock options to Robert Z. Gussin, a Director of Cassava Sciences Inc., constitutes a related party transaction as he is considered a related party to the company.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of director interests with long-term shareholder value.

Next Steps

• The stock options will vest monthly over the next one year.
• The director may choose to exercise the options at any time between the exercisable date and the expiration date, subject to vesting.

Key Dates

Recommendation

Keywords

Cassava Sciences, SAVA, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Corporate Governance